Brief: Replimune Gets Third Try At FDA Approval After Makary Departure- WSJ
29/05/2026 12:33
BRIEF-Replimune Gets Third Try At FDA Approval After Makary Departure- WSJ May 29 (Reuters) -
REPLIMUNE GETS THIRD TRY AT FDA APPROVAL AFTER MAKARY DEPARTURE- WSJ
REPLIMUNE EXPECTED TO ANNOUNCE AGREEMENT WITH FDA TO RESUBMIT ITS ADVANCED MELANOMA TREATMENT FOR APPROVAL - WSJ
Source text: [https://tinyurl.com/bdh4nhte]
Further company coverage: REPL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Replimune
See all newsTrump picks White House adviser Heidi Overton to run FDA, source says (updated)
Brief: Replimune Group, Inc. Files For Mixed Shelf Size Not Disclosed
Brief: Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate Update
Replimune Q1 net loss narrows as expenses decline
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial, Eli Lilly